Forum www.bewet.fora.pl Strona Główna www.bewet.fora.pl
Wszystko o zwierzętach.
 
 FAQFAQ   SzukajSzukaj   UżytkownicyUżytkownicy   GrupyGrupy   GalerieGalerie   RejestracjaRejestracja 
 ProfilProfil   Zaloguj się, by sprawdzić wiadomościZaloguj się, by sprawdzić wiadomości   ZalogujZaloguj 

Usain Bolt YugoRun Aarkstore Enterprise Puma Roma

 
Napisz nowy temat   Odpowiedz do tematu    Forum www.bewet.fora.pl Strona Główna -> Bewet pomaga
Zobacz poprzedni temat :: Zobacz następny temat  
Autor Wiadomość
j5g5xminpy




Dołączył: 16 Lis 2010
Posty: 103
Przeczytał: 0 tematów

Ostrzeżeń: 0/5
Skąd: England

PostWysłany: Śro 12:12, 08 Gru 2010    Temat postu: Usain Bolt YugoRun Aarkstore Enterprise Puma Roma

Understand the important role of employee morale and identify measures to retain key staff.
Key Market Issues



From 19962005, US pharmas sales force nearly doubled to 100,000 to support a 26% increase in practicing physicians. However, a significant number of drugs will lose patent protection over the next four years, 20102014, representing roughly $60bn in total, and the generic share of the drug market has increased from 49% to 74% of total sales in the US from 20002009.





Case studies of issues resulting from workforce reductions and outsourcing of manufacturing and R&D, with numerous examples of pitfalls and best practice.
Scope of this report

Gain insight into strategies that have been used for facility divestitures to achieve optimum returns.
Different companies are adopting various approaches for R&D outsourcing; for example, Eli Lilly plans to outsource 50%, whereas Novartis is committed to a large internal R&D team.

Discovery R&D scientific jobs in the pharmaceutical industry require significant years of education and on the job training; in particular [link widoczny dla zalogowanych], the shift of chemistry jobs overseas will have long-term negative effects on the US pool of chemistry talent that wi
Appreciate the benefits of engaging with key local stakeholders during workforce reductions and site closures, and understand the sanctions which local governments may attempt to impose.
A single reference for comparing details on employment protection regulations in different countries, and for the US highlights of major differences in specific states with large pharma employment
Demonstration of how to achieve a cost-effective workforce reduction while maintaining R&D innovation and manufacturing quality.
Assess inter-country (and within the US inter-state) differences in employment protection regulations.


ategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of legal, productivity, and quality control issues
In 2007, due to the impending patent cliff and the consequent need to cut costs, big pharma began for the first time to outsource chemical API manufacturing to China and India. Prior to this only generic drug companies had manufactured in the two countries. Since then, big pharma has been undergoing waves of layoffs that have been accelerated by the economic downturn, with manufacturing and sales being particularly affected, and outsourcing levels in R&D and manufacturing are expected to increase further in the future.
This report examines the different strategies available for managing the layoffs and site closures resulting from not only the outsourcing of R&D and manufacturing, but also the transition from small-molecules to biologics and the need to exploit new markets. The factors causing change and producing the need for workforce reductions are analysed, and the expected impact across the pharmaceutical workforce in the US is detailed. The consequences of layoffs and site closures in terms of legal compliance, maintenance of productivity, and safeguarding of quality control are discussed in depth. Case studies from the pharmaceutical industry are provided to highlight pitfalls and illustrate best practice. The report concludes with discussion of the long-term risks associated with over-dependence on expansion in nonmarket economies and suggests methods to lower these risks.
Key features of this report

In 2007, global big pharma including AZ, Pfizer, GSK, and BMS, first announced its plans to outsource API manufacturing to China and India; in the same year, of the 1 [link widoczny dla zalogowanych],154 generic drug applications to the US FDA [link widoczny dla zalogowanych], only 13% of the manufacturing plants were in the US, while 43% and 39% of the plants were abroad in China and India respectively.
Identify current and future trends in pharmaceutical industry employment and understand their causes.
Comprehensive coverage of the changes occurring in pharmaceutical industry employment in developed nations.
相关的主题文章:


Pumas Shoes 21 Ten Review! 21 Ten Usain Bolt YugoR

Puma Drift Cat II Choosing The Right Puma Fluxion

[link widoczny dla zalogowanych]


Post został pochwalony 0 razy
Powrót do góry
Zobacz profil autora
Wyświetl posty z ostatnich:   
Napisz nowy temat   Odpowiedz do tematu    Forum www.bewet.fora.pl Strona Główna -> Bewet pomaga Wszystkie czasy w strefie EET (Europa)
Strona 1 z 1

 
Skocz do:  
Możesz pisać nowe tematy
Możesz odpowiadać w tematach
Nie możesz zmieniać swoich postów
Nie możesz usuwać swoich postów
Nie możesz głosować w ankietach

fora.pl - załóż własne forum dyskusyjne za darmo
Powered by phpBB © 2001, 2005 phpBB Group
Regulamin